Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer

Human epidermal growth factor receptor 2 oncogene (HER2-positive) overexpression/amplification occurs in less than 20% of breast cancers and has traditionally been associated with poor prognosis. Development of therapies that target HER2 has significantly improved outcomes for patients with HER2-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Aapro, Matti, Cardoso, Fatima, Curigliano, Giuseppe, Eniu, Alexandru, Gligorov, Joseph, Harbeck, Nadia, Mueller, Andreas, Pagani, Olivia, Paluch-Shimon, Shani, Senkus, Elzbieta, Thürlimann, Beat, Zaman, Khalil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597182/
https://www.ncbi.nlm.nih.gov/pubmed/36279803
http://dx.doi.org/10.1016/j.breast.2022.07.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597182/
https://www.ncbi.nlm.nih.gov/pubmed/36279803
http://dx.doi.org/10.1016/j.breast.2022.07.011

Ejemplares similares